Knight Therapeutics Inc. (TSX: GUD) announced that it has repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. The repayment was funded through strong cash flow generated by its operations in Canada and Latin America, according to the company.
The revolving credit facility continues to provide borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature available subject to certain conditions. This financial flexibility supports Knight’s ongoing growth strategy across its pan-American pharmaceutical business. The repayment demonstrates the company’s ability to generate robust cash flows and manage debt effectively, which may strengthen investor confidence in its financial discipline.
Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. The company’s shares trade on the TSX under the symbol GUD.
The repayment of the credit facility is a significant milestone for Knight, as it reduces interest expenses and improves the company’s balance sheet. By leveraging operational cash flows rather than additional debt or equity, Knight signals that its core business is generating sufficient liquidity to support acquisitions and growth initiatives. This move may also allow the company to pursue further strategic opportunities, such as additional acquisitions or investments in its product pipeline, without over-leveraging.
For the pharmaceutical industry, Knight’s ability to repay debt quickly highlights the potential for specialty pharma companies to successfully integrate acquisitions and generate synergies. The Paladin acquisition, completed in mid-2025, expanded Knight’s portfolio and market presence in Latin America, a region with growing demand for pharmaceutical products. The strong cash flow from these operations underscores the value of the acquisition and the effectiveness of Knight’s commercialization strategy.
Investors and analysts may view this repayment as a positive signal of Knight’s financial health and management’s commitment to prudent capital allocation. The maintained access to up to US$200 million in borrowing capacity also provides a cushion for future investments, whether in research and development, licensing deals, or further acquisitions. As Knight continues to execute its pan-American strategy, the repayment reinforces its position as a resilient player in the pharmaceutical sector.
For more information about the company, visit www.knighttx.com. The full press release is available at https://ibn.fm/8eluB.
